Press coverage about GlaxoSmithKline PLC (NYSE:GSK) has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlaxoSmithKline PLC earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the pharmaceutical company an impact score of 46.4364334473061 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of GlaxoSmithKline PLC (GSK) traded up 0.57% on Monday, reaching $39.01. The company had a trading volume of 1,734,732 shares. The stock has a market capitalization of $95.34 billion, a PE ratio of 37.73 and a beta of 1.03. The company has a 50 day moving average price of $41.69 and a 200 day moving average price of $41.88. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.59.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The business had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. On average, equities research analysts anticipate that GlaxoSmithKline PLC will post $2.85 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be paid a $0.491 dividend. The ex-dividend date of this dividend is Wednesday, August 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a dividend yield of 5.03%. GlaxoSmithKline PLC’s dividend payout ratio is 197.00%.

Several equities research analysts have recently issued reports on GSK shares. TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a report on Friday, May 19th. Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a report on Tuesday, July 18th. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $44.67.

COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline PLC (NYSE:GSK) Given News Sentiment Score of 0.20” was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.